Cancer Clinical Pharmacology

The book considers both the theory and practice of clinical pharmacology where it is relevant to cancer treatment. It covers the basics of clinical pharmacology in oncology and cancer therapeutics, discussing the specific classes of anti-cancer agents in detail. Edited and written by a mix of generalist cancer clinical pharmacologists and sub-specialists within this area, the book allows the reader to develop both general clinical pharmacology skills and specialist knowledge for particular cancer chemotherapy agents.

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees. Key Features: Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities Thoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach

In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely – to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist’s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.

Symposium on Clinical Pharmacology reviews advances in clinical pharmacology, with emphasis on how to materially improve the efficacy of cancer chemotherapy. Topics range from absorption, protein binding, distribution, and excretion of antineoplastic drugs to factors affecting the biotransformation and activity of antitumor drugs. The transport of tumor-inhibitory agents across cell membranes is also examined, together with factors influencing drug selectivity and the mechanisms of clinical drug resistance. This volume is comprised of 23 chapters and begins with a brief summary of the different kinds of pharmacokinetic models and how detailed kinetic investigations of a drug in animals may provide further insight into modes of its clinical use. The next chapter considers the chief factors in determining the effective concentration of a drug at a receptor site as well as the duration and intensity of drug effect, citing antineoplastic agents as examples. The role of enzymatic activation and inactivation in drug selectivity is also discussed, along with the general mechanisms of clinical resistance to cancer chemotherapy; biochemical and pharmacological principles of combination chemotherapy; and the reaction and effects of nitrosoureas. This book will be of interest to clinicians, pharmacologists, and biochemists.

Completely revised and updated for 2014, the Physicians' Cancer Chemotherapy Drug Manual 2014 is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens--both on- and off-label--for the treatment of all the major cancers. Special features: - Revised to reflect rapid advances in the field - A specific chapter focused on profiling antiemetic drug and antiemetic treatment regimens. - Diagrams of drug structures and pathways for many of the agents. - Offers a comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages. - Covers toxicity and drug-drug interactions. - A section on chemotherapy regimens for all major cancers. - Provides an overview of the basic principles of cancer drug therapy.

This book represents the efforts of young oncologists, haematologists, pharmacists and oncology nurses who are highly motivated and encouraged by the significant development of new effective anticancer drugs. Since the discovery of antimetabolites and alkylating agents in the 1940s and 1950s, many new products have been introduced into our daily arsenal not only through chemotherapy agents, but also by means of biological or immunotherapeutic drugs whose side effects differ significantly. The idea of this book was born from a simple observation and confirmation of fact. New doctors in training experience high levels of stress and lack of confidence when confronting cancer patients and explaining a treatment or managing frequent side effects. Patients questions will only add more nervousness, and this will lead to a failure in the doctor-patient relationship, causing the patients mistrust and doctors frustration. Nurses dealing with these patients will suffer pressure too, as many questions regarding antineoplastic drugs will be asked of them and patients expect them to ease their doubts. This feeling of vulnerability in front of a patient, though a part of the maturation process when becoming a professional caretaker, causes discomfort and incertitude. In this context, it is crucial to gain great knowledge about pharmacokinetic and pharmacological features of each active anticancer drug used, as well as the indications, dosages, interactions and toxicities, to be able to face the daily practice of oncology without concerns and manage daily therapeutic complications easily. This may be considered very difficult, taking into account the huge number of active agents doctors manage routinely, but doctors have accepted the challenge and designed a straightforward, comprehensible book to solve this issue. The Easy Book of Cancer Pharmacology provides the means to overcome the problem. It is conceived as an accessible, concise and yet exhaustive tool which displays a vast amounts of knowledge in a very schematic way. It is easy to consult and offers a very practical expertise to develop the ability of managing effectively each antineoplastic agent quickly. It gives the necessary insights to explain this to the patients with confidence. Each chapter reviews one active drug and shows the information with a pragmatic style, and they are divided into different sections. Each section covers distinct aspects of the agent, from general characteristics to more specific details related to clinical pharmacology. In quickly advancing fields such as oncology, such a book is necessary to help update the ever-developing and expanding knowledge of clinicians and patients in an efficient and effective manner.

Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the second leading cause of death worldwide, with its various forms resulting in nearly one out of every six mortalities each year. This book describes all US FDA-approved drugs (up to 2021), such as small molecules, peptides, monoclonal antibodies, whole antibodies, gene therapy, antibody-drug conjugates, cell therapy, and immunotherapies, along with information on their generic and brand names, medical uses, details dosage, mechanisms of actions, pharmacokinetics and side effects. Chemical structures of small molecules, small peptides, antibody-drug conjugates are also provided. This book is ideal for medicinal chemists, oncologists, and pharmacologists, but it will also be indispensable for professional researchers, whether they are working in the clinic or the pharmaceutical industry. Covers precise information on each drug treatment Catalogues and lists all FDA-approved drugs for cancer group by chemical classes Provides easy access to specific drugs

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development